See more : Calliditas Therapeutics AB (publ) (CALT) Income Statement Analysis – Financial Results
Complete financial analysis of Benchmark Holdings plc (BHCCF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Benchmark Holdings plc, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Daimler Truck Holding AG (DTG.DE) Income Statement Analysis – Financial Results
- Kimura Unity Co., Ltd. (9368.T) Income Statement Analysis – Financial Results
- Stratus Properties Inc. (STRS) Income Statement Analysis – Financial Results
- Decentral Life, Inc. (WDLF) Income Statement Analysis – Financial Results
- Addentax Group Corp. (ATXG) Income Statement Analysis – Financial Results
Benchmark Holdings plc (BHCCF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.benchmarkplc.com
About Benchmark Holdings plc
Benchmark Holdings plc, together with its subsidiaries, engages in the provision of technical services, products, and specialist knowledge that supports the development of food and farming industries. The company operates through Genetics, Advanced Nutrition, and Health segments. The Genetics segment offers sea bass/bream, salmon, shrimp, and tilapia breeding technologies and production facilities to the harnesses industry to provide various genetic merit ova. The Advanced Nutrition segment manufactures and provides nutrition and health products to the aquaculture industry. The Health segment provides health products, including Ectosan Vet and CleanTreat medicinal sea lice solutions to the aquaculture market. The company operates in the United Kingdom, Norway, the Faroe Islands, Ecuador, India, Greece, Singapore, Chile, Turkey, rest of the Europe, and internationally. Benchmark Holdings plc was founded in 2000 and is headquartered in Sheffield, the United Kingdom.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 90.37M | 169.48M | 158.28M | 125.06M | 105.57M | 127.34M | 151.47M | 140.17M | 109.38M | 44.20M | 35.35M | 27.55M | 18.55M |
| Cost of Revenue | 46.42M | 82.73M | 75.15M | 59.48M | 50.60M | 61.35M | 77.45M | 77.78M | 58.56M | 28.10M | 20.58M | 14.77M | 10.69M |
| Gross Profit | 43.95M | 86.75M | 83.13M | 65.59M | 54.96M | 66.00M | 74.02M | 62.39M | 50.81M | 16.10M | 14.77M | 12.78M | 7.86M |
| Gross Profit Ratio | 48.63% | 51.19% | 52.52% | 52.44% | 52.06% | 51.82% | 48.87% | 44.51% | 46.46% | 36.42% | 41.78% | 46.39% | 42.38% |
| Research & Development | 2.44M | 6.07M | 6.69M | 7.01M | 7.28M | 12.83M | 12.04M | 13.06M | 11.72M | 6.60M | 2.69M | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.78M | 4.40M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 0.00 | 44.10M | 38.27M | 33.32M | 214.00K | 0.00 | 452.00K | 0.00 | 0.00 | 0.00 | 7.78M | 4.40M |
| Other Expenses | 77.00M | 86.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 79.45M | 92.07M | 90.41M | 69.87M | 63.87M | 126.25M | 81.48M | 75.70M | 56.98M | 24.77M | 12.24M | 7.67M | 4.22M |
| Cost & Expenses | 125.86M | 174.79M | 165.56M | 129.35M | 114.48M | 187.60M | 158.93M | 153.48M | 115.54M | 52.88M | 32.83M | 22.44M | 14.91M |
| Interest Income | 44.00K | 627.00K | 319.00K | 4.19M | 1.08M | 366.00K | 301.00K | 258.00K | 254.00K | 274.00K | 60.00K | 8.00K | 11.00K |
| Interest Expense | 8.05M | 10.50M | 11.42M | 7.99M | 12.78M | 6.09M | 2.43M | 1.96M | 1.19M | 34.00K | 248.00K | 259.00K | 115.00K |
| Depreciation & Amortization | 48.85M | 37.21M | 39.06M | 24.64M | 28.54M | 83.31M | 24.84M | 23.35M | 16.61M | 4.37M | 1.40M | 1.13M | 405.00K |
| EBITDA | 10.97M | 20.74M | 20.54M | 23.45M | 14.34M | 30.93M | 18.85M | 11.56M | -4.58M | -6.96M | 277.00K | 6.24M | 4.05M |
| EBITDA Ratio | 12.14% | 12.24% | 21.67% | 18.90% | 19.76% | 14.42% | 9.81% | 8.25% | 8.89% | -9.13% | 11.29% | 22.66% | 21.86% |
| Operating Income | -35.50M | -5.32M | -7.86M | -5.38M | -10.87M | -61.25M | -9.06M | -7.66M | -20.47M | -11.60M | -1.19M | 5.10M | 3.64M |
| Operating Income Ratio | -39.28% | -3.14% | -4.97% | -4.30% | -10.30% | -48.10% | -5.98% | -5.47% | -18.72% | -26.24% | -3.36% | 18.53% | 19.62% |
| Total Other Income/Expenses | -10.43M | -7.38M | -15.15M | -3.80M | -11.70M | -12.05M | -4.60M | -465.00K | -1.91M | 240.00K | -188.00K | -251.00K | -104.00K |
| Income Before Tax | -45.93M | -12.69M | -23.18M | -9.18M | -22.57M | -73.30M | -13.66M | -8.10M | -22.38M | -11.36M | -1.38M | 4.85M | 3.53M |
| Income Before Tax Ratio | -50.82% | -7.49% | -14.64% | -7.34% | -21.38% | -57.56% | -9.02% | -5.78% | -20.47% | -25.70% | -3.89% | 17.62% | 19.06% |
| Income Tax Expense | -1.65M | 3.37M | 7.27M | 2.40M | 204.00K | -13.00K | -9.27M | -980.00K | -4.04M | 396.00K | -54.00K | 560.00K | 751.00K |
| Net Income | -39.46M | -23.15M | -32.09M | -12.89M | -32.92M | -83.86M | -5.01M | -7.44M | -18.34M | -11.99M | -1.32M | 4.29M | 2.78M |
| Net Income Ratio | -43.67% | -13.66% | -20.27% | -10.31% | -31.19% | -65.85% | -3.31% | -5.31% | -16.77% | -27.12% | -3.72% | 15.59% | 15.00% |
| EPS | -0.05 | -0.02 | -0.05 | -0.02 | -0.05 | -0.15 | -0.01 | -0.01 | -0.04 | -0.06 | -0.01 | 0.03 | 0.02 |
| EPS Diluted | -0.05 | -0.02 | -0.05 | -0.02 | -0.05 | -0.15 | -0.01 | -0.01 | -0.04 | -0.06 | -0.01 | 0.03 | 0.02 |
| Weighted Avg Shares Out | 739.58M | 960.38M | 698.23M | 669.46M | 625.47M | 558.79M | 532.55M | 522.97M | 418.66M | 201.62M | 127.17M | 136.65M | 136.65M |
| Weighted Avg Shares Out (Dil) | 739.58M | 731.94M | 698.23M | 669.46M | 625.47M | 558.79M | 532.55M | 522.97M | 418.66M | 201.62M | 127.17M | 136.65M | 136.65M |
Source: https://incomestatements.info
Category: Stock Reports